Home » BioCancell Receives FDA Approval to Continue Bladder Cancer Trial
BioCancell Receives FDA Approval to Continue Bladder Cancer Trial
Tikcro Technologies announced that BioCancell Therapeutics concluded
the first 18 patient group treated pursuant to a Phase IIb clinical trial of the drug candidate BC-819 for use in superficial bladder cancer.
MarketWatch
MarketWatch
Upcoming Events
-
07May
-
14May
-
30May